ChiCTR1900022366
尚未开始
/
/
/
2019-04-08
/
/
非ST段抬高型心肌梗死
非ST段抬高型心肌梗死患者三甲胺氮氧化物与冠状动脉粥样硬化负荷的关系
非ST段抬高型心肌梗死患者三甲胺氮氧化物与冠状动脉粥样硬化负荷的关系
518055
Aims to evaluate the relationship between plasma TMAO levels, and the complexity and atherosclerotic burden in NSTEMI patients.
连续入组
其它
N/A
N/A
中国医学科学院阜外医院深圳医院
/
100
/
2019-04-15
2020-04-15
/
The present study will include two groups of individuals. The first group will include one hundred NSTEMI patients older than 18 years, those who will undergo emergency or primary coronary angiography or percutaneous coronary intervention (PCI) from 15th April 2019 to 15th April 2020. NSTEMI will define according to current ESC guideline as the presence of acute chest pain, but no persistent ST-segment elevation; electrocardiogram (ECG) change may include ST-segment depression ≥0.05 mV, T-wave inversion ≥0.3 mV or flat T wave, or transient ST-segment elevation ≤0.05 mV or may be normal ECG; and positive elevated troponin T or I and/or CK-MB exceeding the upper limit of normal range. The second group will include healthy individuals without known cardiovascular diseases those who will visit for health screen. The second group purpose will provide the reference interval values for TMAO levels compared to the first group.；
登录查看The exclusion criteria comprises; ST elevation myocardial infarction or stable or unstable coronary artery disease, heart failure, renal or hepatic disease, severe valvular disease, previous history of PCI or CABG, history stroke or bleeding within 3 months, peripheral arterial disease, pregnancy, chronic obstructive lung disease, acute and chronic infection, and history of cancer.；
登录查看中国医学科学院阜外医院深圳医院
518055
药研网2025-10-10
医药观澜2025-10-10
研发客2025-10-10
药筛2025-10-10
医药笔记2025-10-10
正大天晴药业集团2025-10-10
医麦客2025-10-10
医麦客2025-10-10
正大制药订阅号2025-10-10
烟台毓璜顶医院2025-10-10
400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网
